Trial of Rifaximin in Probable Alzheimer's Disease

NCT03856359 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: Rifaximin 550 milligrams (MG)

Sponsor

Duke University

Collaborators

[object Object]